# Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

> **NCT01740648** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Rectal Cancer
- Stage IIA Rectal Cancer
- Stage IIB Rectal Cancer
- Stage IIC Rectal Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Rectal Cancer

## Interventions

- **DRUG:** trametinib
- **DRUG:** fluorouracil
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT01740648
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-26
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-09-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740648, "Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01740648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*